10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2021 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2021 10-K (Filed: Feb 18, 2022) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2021 | Dec 31, 2020 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $ 9,799 | 6,838 |
| Investments, primarily bank time deposits and U.S. treasury bills | 450 | 310 |
| Trade receivables, less allowances of - 2021: $519; 2020: $460 | 6,487 | 6,414 |
| Inventories: | ||
| Finished products | 3,081 | 3,030 |
| Work in process | 694 | 712 |
| Materials | 1,382 | 1,270 |
| Total inventories | 5,157 | 5,012 |
| Other prepaid expenses and receivables | 2,346 | 1,867 |
| Total current assets | 24,239 | 20,441 |
| Investments | 816 | 821 |
| Property and equipment, at cost: | ||
| Land | 525 | 538 |
| Buildings | 4,007 | 4,014 |
| Equipment | 13,528 | 12,884 |
| Construction in progress | 1,304 | 1,357 |
| Property and equipment, at cost | 19,364 | 18,793 |
| Less: accumulated depreciation and amortization | 10,405 | 9,764 |
| Net property and equipment | 8,959 | 9,029 |
| Intangible assets, net of amortization | 12,739 | 14,784 |
| Goodwill | 23,231 | 23,744 |
| Deferred income taxes and other assets | 5,212 | 3,729 |
| Total Assets | 75,196 | 72,548 |
| Liabilities and Shareholders' Investment | ||
| Current liabilities: | ||
| Short-term borrowings | 0 | 213 |
| Trade accounts payable | 4,408 | 3,946 |
| Salaries, wages and commissions | 1,625 | 1,416 |
| Other accrued liabilities | 5,181 | 5,165 |
| Dividends payable | 831 | 798 |
| Income taxes payable | 306 | 362 |
| Current portion of long-term debt | 754 | 7 |
| Total current liabilities | 13,105 | 11,907 |
| Long-term debt | 17,296 | 18,527 |
| Post-employment obligations and other long-term liabilities | 8,771 | 9,111 |
| Commitments and contingencies | ||
| Shareholders' investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2021: 1,985,273,421; 2020: 1,981,156,896 | 24,470 | 24,145 |
| Common shares held in treasury, at cost - Shares: 2021: 221,191,228; 2020: 209,926,622 | (11,822) | (10,042) |
| Earnings employed in the business | 31,528 | 27,627 |
| Accumulated other comprehensive income (loss) | (8,374) | (8,946) |
| Total Abbott Shareholders' Investment | 35,802 | 32,784 |
| Noncontrolling interests in subsidiaries | 222 | 219 |
| Total Shareholders' Investment | 36,024 | 33,003 |
| Total Liabilities and Shareholders' Investment | 75,196 | 72,548 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |